Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Files An 8-K Regulation FD Disclosure

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01. Regulation FD Disclosure.

On March 13, 2017, Sucampo Pharmaceuticals, Inc. (Company) will
make a corporate update presentation at one-on-one meetings with
analysts and investors in New York at the 29th Annual
Roth Conference. All meetings will include written communication
comprised of slides. The slides from the presentation are being
furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in the presentation furnished as
Exhibit 99.1 shall not be deemed filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), and is not incorporated by reference into any of the
Companys filings under the Securities Act of 1933, as amended, or
the Exchange Act, whether made before or after the date hereof,
except as shall be expressly set forth by specific reference in
any such filing.

Item 9.01 Financial Statements and Exhibits.


Exhibit Number ExhibitDescription
99.1 Presentation titled Sucampo Pharmaceuticals, Inc. Corporate
Update dated March 13, 2017.

About Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom. It offers AMITIZA for the treatment of constipation and RESCULA for the lowering of intraocular pressure (IOP). Its products under development include cobiprostone, RTU-1096 and RTU-009.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Recent Trading Information

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) closed its last trading session up +0.09 at 10.59 with 1,551,848 shares trading hands.

An ad to help with our costs